|
Could not find this reference - please provide more specific URL
From the news coming out of the FDA advisory panel, which recommended FDA rejection of Avastin for metastasized bc, because of its harsh side effects and the study's failure to find longer survival rates (only lengthened time-to-recurrence, but often with reduced QOL), I'm not sure that the referenced publication is indicative of current data collection.
|